Sepsis: Is there room for vasopressin?

Sepsis

Volumn 4, Issue 2, 2001, Pages 169-175

  Holmes, Cheryl L ^a   Russell, James A ^a   Walley, Keith R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Hemodynamics; Sepsis; Shock; Vasopressin

Indexed keywords

NITRIC OXIDE; VASOPRESSIN;

ADULT; AGED; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RESUSCITATION; REVIEW; SEPSIS; VASODILATATION;

EID: 0035020151     PISSN: 13850229     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011415123190     Document Type: Review

References (75)

1. Increase in national hospital discharge survey rates for septicemia - United States, 1979-1987
2. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy
3. Has the mortality of septic shock changed with time
4. Hemodynamic determinants of mortality in human septic shock
5. Early hemodynamic course of septic shock
6. The relationship between cardiac reserve and survival in critically ill patients receiving treatment aimed at achieving supranormal oxygen delivery and consumption
7. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?
8. Renovascular resistance and noradrenaline
9. Endogenous and exogenous catecholamines in critical care medicine
10. Shock. Diagnosis and management
11. Effects of nitric oxide in septic shock
12. Vasopressin in septic shock - A useful or dangerous agent?
13. Vasopressin pressor hypersensitivity in vasodilatory septic shock
14. Vasopressin deficiency contributes to the vasodilation of septic shock
15. Low-dose vasopressin in the treatment of vasodilatory septic shock
16. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement
17. Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent
18. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation
19. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock
20. Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery
21. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors
22. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure
23. Circulatory effects following the intravenous administration of Pitressin in normal persons and in patients with hypertension and angina pectors
24. The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension
25. Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension
26. Vasopressin infusion in SIRS and septic shock: A randomized controlled trial
27. Vasopressin infusion increases mean arterial pressure and urine output in patients having severe septic shock
28. Distribution of oxytocin and vasopressin in the rat supraoptic and paraventricular nucleus
29. Central nervous system mediators of vasopressin release
30. Control of release of vasopressin by neuroendocrine reflexes
31. Baroreceptor regulation of vasopressin and renin secretion: Low-pressure versus high-pressure receptors
32. Renin and vasopressin responses to graded reductions in atrial pressure in conscious dogs
33. Effects of separate and concurrent osmotic and volume stimuli on plasma ADH in sheep
34. The effects of hypotension and hypovolaemia on the liberation of vasopressin during haemorrhage in the unanaesthetized monkey (Macaca mulatta)
35. Cardiac and arterial baroreceptor influences in release of vasopressin and renin during hemorrhage
36. Response of vasopressin and nonrepinephrine to lower body negative pressure in humans
37. Arterial pulse pressure and vasopressin release in humans during lower body negative pressure
38. Cardiovascular and endocrine responses to head-up tilt and vasopressin infusion in humans
39. Renin response to stimulation of cardiopulmonary mechanoreceptors in man
40. Effect of moderate hemorrhage in humans on plasma ADH and renin
41. The osmoregulation of vasopressin
42. Influence of volume changes on osmolality-vasopressin relationships in conscious dogs
43. Osmotic and nonosmotic control of vasopressin release
44. The role of adenosine 3′,5′-phosphate in the action of antidiuretic hormone
45. Human vascular endothelial cells express oxytocin receptors
46. Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake
47. A radioimmunoassay for plasma argine-vasopressin in man and dog: Application to physiological and pathological states
48. Evidence and quantification of the vasopressin arterial pressure control system in the dog
49. Ventricular receptors stimulate vasopressin release during hemorrhage
50. Role of vasopressin in blood pressure regulation in conscious water-deprived dogs
51. Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs
52. Interactions of vasopressin with the area postrema in arterial baroreflex function in conscious rabbits
53. Role of V1 receptors in the action of vasopressin on the baroreflex control of heart rate
54. Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog
55. Pharmacology and clinical perspectives of vasopressin antagonists
56. Blood pressure, pulse, and neurohumoral responses to nitroprusside-induced hypotension in normotensive aging men
57. Role of vasopressin in cardiovascular and blood pressure regulation
58. The effect of vasopressin upon the vasculature of the isolated perfused rat kidney
59. Cardiac output distribution during vasopressin infusion or dehydration in conscious dogs
60. The effect of vasopressin on renal blood flow and its distribution in the rat
61. Renal microvascular effects of vasopressin and vasopressin antagonists
62. Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure
63. Elevated plasma vasopressin concentrations during endotoxin and E. coli shock
64. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock
65. Spectral analysis of heart rate variability in the sepsis syndrome
66. Role of vasopressin in the control of arterial pressure
67. Opposing alpha- and beta-adrenergic mechanisms mediate dose-dependent actions of noradrenaline on supraoptic vasopressin neurones in vivo
68. Alpha 1-adrenergic receptor activation depolarizes rat supraoptic neurosecretory neurons in vitro
69. Role of nitric oxide in the regulation of renin and vasopressin secretion
70. Role of NO on vasopressin and oxytocin release and blood pressure responses during osmotic stimulation in rats
71. Signal transduction of V1-vascular vasopressin receptors
72. Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery
73. The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog
74. Physiological roles and properties of potassium channels in arterial smooth muscle
75. Vasopressin modulates K(+)-channel activities of cultured smooth muscle cells from porcine coronary artery